<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602406</url>
  </required_header>
  <id_info>
    <org_study_id>CLJM716X2102</org_study_id>
    <secondary_id>2011-004881-13</secondary_id>
    <nct_id>NCT01602406</nct_id>
  </id_info>
  <brief_title>Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer</brief_title>
  <official_title>A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, dose escalation, phase I study to estimate the Maximum&#xD;
      Tolerated Dose (MTD) or a lower Recommended Dose for Expansion (RDE) of LJM716 in combination&#xD;
      with trastuzumab in patients with Human Epidermal growth factor Receptor 2 (HER2)&#xD;
      overexpressing Metastatic Breast Cancer (MBC) or gastric cancer (MGC). The study consists of&#xD;
      a dose escalation part and a dose expansion part. LJM716 will be administered intravenously&#xD;
      once weekly unless a less frequent dosing regimen such as every 2 weeks or once every 4 weeks&#xD;
      is introduced. Patients will continue on their trastuzumab dosing, administered intravenously&#xD;
      once weekly at 2mg/kg. During dose escalation, a minimum of 15 patients are anticipated to be&#xD;
      treated in successive cohorts. The dose escalation will continue until the MTD/RDE is&#xD;
      declared. The RDE dose selected will either be the MTD or a dose below the MTD based on&#xD;
      safety and Pharmacokinetic/Pharmacodynamic (PK/PD) considerations. Following the MTD/RDE&#xD;
      declaration, approximately 20 MBC and 20 MGC patients will be enrolled in separate arms in&#xD;
      the dose expansion part and treated at the MTD/RDE to further assess the safety,&#xD;
      tolerability, and anti-tumor activity of the combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2012</start_date>
  <completion_date type="Actual">August 2, 2017</completion_date>
  <primary_completion_date type="Actual">August 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of Dose Limiting Toxicities</measure>
    <time_frame>4 weeks</time_frame>
    <description>Incidence of dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>4 months</time_frame>
    <description>Safety assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events</measure>
    <time_frame>4 months</time_frame>
    <description>Safety assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response to LJM716 in tumor tissue</measure>
    <time_frame>3 months</time_frame>
    <description>Post-treatment change from baseline in pHER3 levels in the tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18 months</time_frame>
    <description>Efficacy assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>18 months</time_frame>
    <description>Efficacy assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of anti-LJM716 antibodies</measure>
    <time_frame>4 months</time_frame>
    <description>Incidence of antibodies against LJM716</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of LJM716 when administered in combination with trastuzumab</measure>
    <time_frame>4 months</time_frame>
    <description>PK profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of partial responses according to Response Evaluation Criteria In Solid Tumors (RECIST)</measure>
    <time_frame>every 2 months up to 18 months</time_frame>
    <description>Efficacy assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of complete responses according to RECIST</measure>
    <time_frame>every 2 months up to 18 months</time_frame>
    <description>Efficacy assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of stable disease according to RECIST</measure>
    <time_frame>every 2 months up to 18 months</time_frame>
    <description>Efficacy assessment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Advanced HER2-positive Breast Cancer or Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>LJM716 in combination with trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LJM716</intervention_name>
    <description>LJM716</description>
    <arm_group_label>LJM716 in combination with trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab</description>
    <arm_group_label>LJM716 in combination with trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed HER-2 positive, metastatic or non-operable locally advanced&#xD;
             breast or gastric cancer&#xD;
&#xD;
          -  Metastatic breast cancer patients must have received a minimum of 1 and a maximum of 3&#xD;
             prior anti HER2 based regimens with documented progression on the most recent regimen&#xD;
             which must contain trastuzumab, ado-trastuzumab emtansine or lapatinib&#xD;
&#xD;
          -  Metastatic gastric cancer patients must have received a minimum of 1 and a maximum of&#xD;
             2 prior anti HER2 based regimens with documented progression on the most recent&#xD;
             regimen which must contain trastuzumab or ado-trastuzumab emtansine&#xD;
&#xD;
          -  During the dose expansion part of study, all patients must have at least one&#xD;
             measurable lesion as defined by RECIST criteria.&#xD;
&#xD;
          -  Patients must have at least one prior trastuzumab-containing regimen&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status â‰¤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Central Nervous System (CNS) metastasis which are: symptomatic or&#xD;
             require treatment for symptom control and/or growing&#xD;
&#xD;
          -  Prior treatment with any anti-HER3 (Human Epidermal growth factor Receptor 3)&#xD;
             treatment&#xD;
&#xD;
          -  Impaired cardiac function&#xD;
&#xD;
          -  Prior to the first dose of study treatment, patients who have received systemic&#xD;
             antineoplastic therapy or any investigational therapy within 4 weeks or within 5 half-&#xD;
             lives of the therapy prior to starting study treatment, whichever is shorter, or for&#xD;
             cyclical therapy, within one cycle length (e.g. 6 weeks for nitrosourea, mitomycin-C).&#xD;
&#xD;
          -  Patients who have a history of primary malignancy other than that being treated in&#xD;
             this study, and currently requires active clinical intervention.&#xD;
&#xD;
          -  Patients who do not have an archival tumor sample (or sections of it) available or&#xD;
             readily obtainable.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17162</url>
    <description>Results for CLJM716X2102 from the Novartis Clinical Trials Website</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced HER2-positive Breast cancer or Gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

